p.89 抽出テキスト

266. Tomasoni D, Benson L, Gatti P, Villaschi A, Ljungman C, Metra M, et al. Cardiac resynchronization therapy for enabling guideline-directed medical therapy optimization in heart failure. Eur J Heart Fail 2025;27:1820–33. https://doi.org/10.1002/ejhf.3719 267. Martens P, Verbrugge FH, Nijst P, Dupont M, Mullens W. Changes in loop diuretic dose and outcome after cardiac resynchronization therapy in patients with heart failure and reduced left ventricular ejection fractions. Am J Cardiol 2017;120:267–73. https://doi.org/10.1016/j.amjcard.2017.04.021 268. Hoppe LK, Muhlack DC, Koenig W, Carr PR, Brenner H, Schottker B. Association of abnormal serum potassium levels with arrhythmias and cardiovascular mortality: a systematic review and meta-analysis of observational studies. Cardiovasc Drugs Ther 2018;32:197–212. https://doi.org/10.1007/ s10557-018-6783-0 269. Anker SD, Kosiborod M, Zannad F, Pina IL, McCullough PA, Filippatos G, et al. Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS-9) in heart failure patients: results from a phase 3 randomized, double-blind, placebo-controlled trial. Eur J Heart Fail 2015;17:1050–6. https://doi.org/ 10.1002/ejhf.300 270. Pitt B, Anker SD, Bushinsky DA, Kitzman DW, Zannad F, Huang IZ, et al. Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. Eur Heart J 2011;32:820–8. https://doi. org/10.1093/eurheartj/ehq502 271. Butler J, Anker SD, Lund LH, Coats AJS, Filippatos G, Siddiqi TJ, et al. Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial. Eur Heart J 2022;43:4362–73. https:// doi.org/10.1093/eurheartj/ehac401 272. Kosiborod MN, Cherney DZI, Desai AS, Testani JM, Verma S, Chinnakondepalli K, et al. Sodium zirconium cyclosilicate for management of hyperkalemia during spironolactone optimization in patients with heart failure. J Am Coll Cardiol 2024;85:971–84. https://doi.org/10.1016/j.jacc. 2024.11.014 273. Mullens W, Damman K, Testani JM, Martens P, Mueller C, Lassus J, et al. Evaluation of kidney function throughout the heart failure trajectory—a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2020;22:584–603. https://doi.org/10.1002/ ejhf.1697 274. Packer M, Poole-Wilson PA, Armstrong PW, Cleland JG, Horowitz JD, Massie BM, et al. Comparative effects of low and high doses of the angiotensinconverting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 1999;100:2312–8. https://doi. org/10.1161/01.cir.100.23.2312 275. Investigators S, Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293–302. https://doi. org/10.1056/NEJM199108013250501 276. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 1995;273:1450–6. https://doi.org/10.1001/jama.1995.03520420066040 277. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429–35. https://doi.org/10.1056/NEJM198706043162301 278. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin–neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371:993–1004. https://doi.org/10.1056/NEJMoa1409077 279. Damman K, Gori M, Claggett B, Jhund PS, Senni M, Lefkowitz MP, et al. Renal effects and associated outcomes during angiotensin–neprilysin inhibition in heart failure. JACC Heart Fail 2018;6:489–98. https://doi.org/10.1016/j. jchf.2018.02.004 280. Desai AS, Vardeny O, Claggett B, McMurray JJ, Packer M, Swedberg K, et al. Reduced risk of hyperkalemia during treatment of heart failure with mineralocorticoid receptor antagonists by use of sacubitril/valsartan compared with enalapril: a secondary analysis of the PARADIGM-HF trial. JAMA Cardiol 2017;2:79–85. https://doi.org/10.1001/jamacardio.2016.4733 281. Velazquez EJ, Morrow DA, DeVore AD, Duffy CI, Ambrosy AP, McCague K, et al. Angiotensin-e in acute decompensated heart failure. N Engl J Med 2019; 380:539–48. https://doi.org/10.1056/NEJMoa1812851 282. Morrow DA, Velazquez EJ, DeVore AD, Desai AS, Duffy CI, Ambrosy AP, et al. Clinical outcomes in patients with acute decompensated heart failure randomly assigned to sacubitril/valsartan or enalapril in the PIONEER-HF trial. Circulation 2019;139:2285–8. https://doi.org/10.1161/CIRCULATIONAHA. 118.039331 283. Wachter R, Senni M, Belohlavek J, Straburzynska-Migaj E, Witte KK, Kobalava Z, et al. Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study. Eur J Heart Fail 2019;21: 998–1007. https://doi.org/10.1002/ejhf.1498 284. Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, et al. Effects of candesartan in patients with chronic heart failure and reduced leftventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003;362:772–6. https://doi. org/10.1016/S0140-6736(03)14284-5 285. Konstam MA, Neaton JD, Dickstein K, Drexler H, Komajda M, Martinez FA, et al. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet 2009;374:1840–8. https://doi.org/10.1016/S0140-6736(09)61913-9 286. Cohn JN, Tognoni G; Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667–75. https://doi.org/10.1056/ NEJMoa010713 287. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001–7. https://doi.org/10.1016/S0140-6736(99)04440-2 288. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999;353:9–13. https://doi.org/10.1016/S0140-6736(98)11181-9 289. Beta-Blocker Evaluation of Survival Trial Investigators; Eichhorn EJ, Domanski MJ, Krause-Steinrauf H, Bristow MR, Lavori PW. A trial of the betablocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001;344:1659–67. https://doi.org/10.1056/NEJM200105313442202 290. Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A, Borbola J, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005;26:215–25. https://doi.org/10.1093/ eurheartj/ehi115 291. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344: 1651–8. https://doi.org/10.1056/NEJM200105313442201 292. Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003;362:7–13. https:// doi.org/10.1016/S0140-6736(03)13800-7 293. Kotecha D, Holmes J, Krum H, Altman DG, Manzano L, Cleland JG, et al. Efficacy of beta blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. Lancet 2014;384:2235–43. https://doi.org/10.1016/S0140-6736(14)61373-8 294. Swedberg K, Komajda M, Bohm M, Borer JS, Ford I, Dubost-Brama A, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010;376:875–85. https://doi.org/10. 1016/S0140-6736(10)61198-1 295. Armstrong PW, Pieske B, Anstrom KJ, Ezekowitz J, Hernandez AF, Butler J, et al. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med 2020;382:1883–93. https://doi.org/10.1056/NEJMoa1915928 296. Butler J, Anstrom KJ, Armstrong PW. Comparing the benefit of novel therapies across clinical trials: insights from the VICTORIA trial. Circulation 2020; 142:717–9. https://doi.org/10.1161/CIRCULATIONAHA.120.047086 297. Butler J, McMullan CJ, Anstrom KJ, Barash I, Bonaca MP, Borentain M, et al. Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet 2025;406:1341–50. https://doi.org/10.1016/S0140-6736(25)01665-4 298. Zannad F, O’Connor CM, Butler J, McMullan CJ, Anstrom KJ, Barash I, et al. Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials. Lancet 2025;406:1351–62. https://doi.org/10.1016/ S0140-6736(25)01682-4 299. Butler J, Fioretti F, McMullan CJ, Anstrom KJ, Barash I, Bonaca MP, et al. Vericiguat and mortality in heart failure and reduced ejection fraction: the VICTOR trial. Eur Heart J 2026;47:683–97. https://doi.org/10.1093/ eurheartj/ehaf655 300. Taylor AL, Ziesche S, Yancy C, Carson P, D’Agostino R Jr, Ferdinand K, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004;351:2049–57. https://doi.org/10.1056/ NEJMoa042934 301. Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med 1986;314:1547–52. https://doi.org/10.1056/NEJM198606123142404 302. Ahmed A, Pitt B, Rahimtoola SH, Waagstein F, White M, Love TE, et al. Effects of digoxin at low serum concentrations on mortality and Downloaded from academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehag100/8766302 by guest on 31 August 2026